- 935U83
- A-74704, A-77003 & A-80987
- AL-721
- ALX40-4C
- AMD3100
- Aplaviroc
- Ampligen
- Atevirdine
- Aztec
- BB-10010
- Butyl DNJ
- Capravirine
- Castanospermine
- Compound Q
- DAPD
- DFC (dexelvucitabine)
- DMP-450
- dOTC
- DPC 083
- DPC 681 and DPC 684
- DPC 961 and DPC 963
- Emivirine
- FLT
- GEM 92
- GW420867X
- KNI-272
- L-697,661
- Lithium gamma-linolenate
- Lodenosine
- Loviride
- Oxpentifylline
- Quinotaline
- RO033-4649
- Ro 24-7429
- SC-52151 & SC-55389A
- SID791
- SPC3
dOTC
dOTC is a failed anti-HIV drug that was developed by BioChem Pharma. Its development was suspended in 1999 when toxicity developed in cynomolgus monkeys given the drug for over six months.
dOTC is a nucleoside reverse transcriptase inhibitor similar in structure to 3TC (lamivudine, Epivir) and FTC (emtricitabine, Emtriva). A related compound, AVX754, is currently under development by Avexa.
latest aidsmap news
- Fluconazole shown to be more effective against cryptococcal meningitis at higher dose
- Promising early results for large-scale study of community-level HIV prevention initiative
- GNP+ launches website documenting global HIV exposure / transmission laws and prosecutions
- Widespread resistance to antiretrovirals among children in the Central African Republic
- Children starting HIV treatment in sub-Saharan Africa have a low risk of death
- Different paediatric responses to antiretroviral therapy in Uganda and the United Kingdom/Ireland may reflect differences in nutrition and access to cotrimoxazole
- Rare abacavir liver side-effects reported
- Abacavir treatment doesn't cause changes in biomarkers linked to heart attack, suggests small study
- Traditional healers could play key role in ART rollout
- HIV testing for mothers and children must expand, UN report shows